Blog
RSS FeedPosted by Michael Wonder on 25 Apr 2024
Children and teenagers with an aggressive form of brain cancer set to benefit after NICE recommends new life-extending drug combination treatment
24 April 2024 - A new targeted drug combination treatment, described as a ‘step-change in care’ for children and young ...
Posted by Michael Wonder on 24 Apr 2024
Pembrolizumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with advanced biliary tract cancer
24 April 2024 - NICE is unable to make a recommendation on the use of pembrolizumab (Keytruda) in combination with gemcitabine ...
Posted by Michael Wonder on 16 Apr 2024
DoH published revised agenda for July 2024 PBAC meeting (12 April 2024)
12 April 2024 - Version 2 of the agenda for the July 2024 PBAC meeting is now available; two minor ...
Posted by Michael Wonder on 15 Apr 2024
Updates to the HTA Policy and Methods Review Reference Committee (15 April 2024)
15 April 2024 - The HTA Review Reference Committee is finalising its report and recommendations to the Australian Government having ...
Posted by Michael Wonder on 14 Apr 2024
HTA review - is today D day?
15 April 2024 - The review is due to be completed by 15 April 2024 (today). ...
Posted by Michael Wonder on 11 Apr 2024
NICE issues final draft guidance for use of remdesivir and also for tixagevimab-cilgavimab (Evusheld) for treatment of COVID-19
9 April 2024 - Final draft guidance for remdesivir and for tixagevimab with cilgavimab has been published by NICE. ...
Posted by Michael Wonder on 11 Apr 2024
170,000 people in England to have further treatment choice for preventing migraine attacks
11 April 2024 - In final draft guidance published today NICE has recommended atogepant, the first of a new type of ...
Posted by Michael Wonder on 11 Apr 2024
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS
11 April 2024 - Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia. ...
Posted by Michael Wonder on 10 Apr 2024
Cabozantinib maleate in combination with nivolumab for the first-line treatment of patients with advanced renal cell carcinoma
10 April 2024 - NICE has published final evidence-based recommendations on the use of cabozantinib maleate (Cabometyx) in combination with ...
Posted by Michael Wonder on 08 Apr 2024
SMC - April 2024 decisions
8 April 2024 - The SMC has today published advice on seven medicines. ...
Posted by Michael Wonder on 05 Apr 2024
Public summary documents – December 2023 PBAC meeting
5 April 2024 - The public summary documents (positive recommendations and subsequent decisions not to recommend) from the December 2023 PBAC ...
Posted by Michael Wonder on 04 Apr 2024
New model validation tool to support economic evaluations of health technologies
1 April 2024 - CADTH has developed a comprehensive and accessible tool to support the validation of economic models used in ...
Posted by Michael Wonder on 03 Apr 2024
Agenda for the July 2024 PBAC meeting
3 April 2024 - The agenda for the July 2024 PBAC meeting is now available. ...
Posted by Michael Wonder on 03 Apr 2024
Dostarlimab in combination with platinum-based chemotherapy for the treatment of patients with advanced or recurrent, high microsatellite instability or mismatch repair deficiency endometrial cancer
3 April 2024 - NICE has published final evidence-based recommendations on the use of dostarlimab (Jemperli) in combination with platinum-based ...
Posted by Michael Wonder on 02 Apr 2024
Polatuzumab vedotin in untreated diffuse large B-cell lymphoma: one step forward, two steps back
2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...